Related Experiment Video
Updated: May 14, 2026
08:40
Methyl-binding DNA capture Sequencing for Patient Tissues
Published on: October 31, 2016
Multiparameter DNA content analysis identifies distinct groups in primary breast cancer
J H S Dayal1, M J Sales, W E Corver
1Dundee Cancer Centre, Ninewells Hospital and Medical School, University of Dundee, Clinical Research Centre Building, Dundee DD1 9SY, UK.
British Journal of Cancer
|February 16, 2013
Summary
Multiparametric flow cytometry accurately assesses breast cancer DNA content. Tumour DNA index correlates with specific biomarkers and high S-phase fraction indicates poor survival.
Area of Science:
- Oncology
- Biotechnology
- Genomics
Background:
- Multiparameter flow cytometry is a reliable method for determining tumour DNA content in formalin-fixed paraffin-embedded (FFPE) tissue.
- This study investigated clinical and pathological associations of DNA content in primary breast cancer using an advanced multiparametric technique.
Purpose of the Study:
- To examine the clinical and pathological associations of DNA content in primary breast cancer.
- To utilize an improved multiparametric flow cytometry technique for DNA content analysis.
Main Methods:
- Analyzed FFPE tissue from 201 primary breast cancers using multiparameter flow cytometry.
- Categorized cancers by DNA content (DNA index - DI) and calculated S-phase fraction (SPF%) using ModFit software.
- Employed Binary Logistic Regression and Cox's Regression for association analysis.
Main Results:
- Low DI tumors associated with progesterone receptor-positive status.
- Intermediate DI tumors linked to p53 mutations; high DI tumors correlated with HER2-positive status.
- High SPF% (≥10%) independently associated with poorer overall survival.
Conclusions:
- Multiparametric flow analysis of FFPE tissue accurately assesses tumor DNA content.
- Tumor DNA content and subpopulations correlate with prognostic biomarkers and potential therapy response.
- DNA content alterations offer insights into mechanisms of clinically significant biomarker changes in breast cancer.
